The Need

Innovative solutions to promote life-changing
therapies for head and neck cancer patients

Yearly 18M new cases of solid tumor cancer patient are prognosed, 30% of them are unfit to chemotherapy treatments due to low BMI, severe side effects causing them to quite the course of chemotherapy, or their tumors micro-environment prevents the chemotherapy from penetrating the tumor and reach cancer cells.

Intragel chose head and neck cancer (HNC) as its first indication, ), as this type of cancer is often diagnosed at late stages, resulting in a generally poor prognosis and advanced stage cancer.

Consequently, from of the 700,000 new HNC patients 50-60% become unfit for chemotherapy, making it a huge unmet need which Intragel is aiming to tackle.

• 100% Client Satisfaction

• World Class Worker